Gastrointestinal Cancers: mCRC (Issue 8) | Special Reports

Pessimism Surrounds VEGF Inhibitors in Advanced Gastric Cancer

May 26, 2016

Clinical Articles

When a recent trial found that apatinib, an experimental VEGFR inhibitor, met its clinical endpoint and showed efficacy as a third-line therapy in treating advanced refractory stomach cancer, one might have expected at least two cheers. After all, gastric cancer is the third most fatal form of the disease globally, and there is currently no standard third-line treatment for advanced patients.

The Link Between Helicobacter Pylori and Gastric Cancer

May 26, 2016

Clinical Articles

Keith T. Wilson, MD, Thomas F. Frist, Sr. Chair in Medicine, Professor, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center explains the link between helicobacter pylori (H pylori) and gastric cancer.